Substituted Amides Inhibit 11βHSD1 for Metabolic Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic syndrome and type 2 diabetes are inadequate in modulating 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) activity, leading to unaddressed insulin resistance, dyslipidemia, and increased cardiovascular risk.
Innovation Solution
Development of substituted amides that inhibit 11βHSD1 activity, reducing intracellular active glucocorticoid levels, thereby treating conditions like metabolic syndrome, type 2 diabetes, and related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for metabolic syndrome and type 2 diabetes are used, then general symptom management is achieved, but 11βHSD1 activity modulation is inadequate, leading to unaddressed insulin resistance and cardiovascular risk
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (substituted amides with particular chemical formulas) that selectively modulate 11βHSD1 enzyme activity. The chemical parameters of the compounds are optimized to achieve desired enzymatic inhibition while maintaining safety profiles, directly addressing the inadequate 11βHSD1 modulation in current treatments
Solution Approach 2:
The patent introduces substituted amide compounds as intermediary substances that mediate between the treatment goal and the biological system. These compounds act as intermediaries by selectively binding to and modulating 11βHSD1 enzyme activity, thereby indirectly addressing insulin resistance and cardiovascular risk factors through glucocorticoid metabolism regulation
2Reliability
If 11βHSD1 activity is strongly inhibited, then intracellular active glucocorticoid levels decrease, but potential off-target effects and safety concerns may arise
Solution Approach 1:
The patent applies local quality by designing compounds that selectively target 11βHSD1 enzyme in specific tissues (liver, adipose tissue, skeletal muscle, pancreas) where the enzyme is most relevant to metabolic syndrome pathogenesis. The molecular structure is optimized to achieve tissue-selective modulation, decreasing intracellular glucocorticoid levels in metabolic tissues while minimizing systemic off-target effects
Solution Approach 2:
The patent employs small molecule compounds with specific pharmacokinetic properties that allow for controlled, transient 11βHSD1 inhibition. The compounds are designed to be metabolized and eliminated at appropriate rates, providing temporary but effective glucocorticoid modulation without long-term accumulation or persistent off-target effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The substituted amides effectively decrease intracellular active glucocorticoid levels, providing a therapeutic benefit for metabolic syndrome, type 2 diabetes, and associated conditions by modulating 11βHSD1 activity, thereby improving insulin sensitivity and reducing cardiovascular risks.
Implementation Method 1
The substituted amides effectively decrease intracellular active glucocorticoid levels, providing a therapeutic benefit for metabolic syndrome, type 2 diabetes, and associated conditions by modulating 11βHSD1 activity
Data Source
AI summary
The use of substituted amides for modulating the activity of 11ß-hydroxysteroid dehydro-genase type 1 (11ßHSD1) and the use of these compounds as pharmaceutical composi-tions, are described. Also a novel class of substituted amides, their use in therapy, phar-maceutical compositions comprising the compounds, as well as their use in the manufac-ture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11ßHSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active gluco-corticoid is desirable.